All Stories

  1. Differential response to a combination of full-dose osimertinib and crizotinib in a patient with EGFR-mutant non-small cell lung cancer and emergent MET amplification

    Article • Lung Cancer Targets and Therapy, March 2019, Dove Medical Press

    Viola Zhu

  2. Dramatic response to alectinib in a lung cancer patient with a novel VKORC1L1-ALK fusion and an acquired ALK T1151K mutation

    Article • Lung Cancer Targets and Therapy, November 2018, Dove Medical Press

    Viola Zhu

  3. Safety of alectinib for the treatment of metastatic ALK-rearranged non-small cell lung cancer

    Article • Expert Opinion on Drug Safety, March 2017, Taylor & Francis

    Viola Zhu